NCT01630590View on ClinicalTrials.gov

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 8, 2014

Primary Completion Date

April 6, 2021

Study Completion Date

April 6, 2021

Conditions
Prostate Cancer
Interventions
DRUG

Cabozantinib

Starting dose of 60 mg by mouth every day of a 21 day cycle.

DRUG

Androgen Ablation Therapy

Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

collaborator

High Impact Clinical Research Support Program

OTHER

lead

M.D. Anderson Cancer Center

OTHER

NCT01630590 - Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter